These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 24680675)

  • 21. Dopamine D3/D2 Receptor Antagonist PF-4363467 Attenuates Opioid Drug-Seeking Behavior without Concomitant D2 Side Effects.
    Wager TT; Chappie T; Horton D; Chandrasekaran RY; Samas B; Dunn-Sims ER; Hsu C; Nawreen N; Vanase-Frawley MA; O'Connor RE; Schmidt CJ; Dlugolenski K; Stratman NC; Majchrzak MJ; Kormos BL; Nguyen DP; Sawant-Basak A; Mead AN
    ACS Chem Neurosci; 2017 Jan; 8(1):165-177. PubMed ID: 27715007
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Dopamine D3 and D4 receptor antagonists: synthesis and structure--activity relationships of (S)-(+)-N-(1-Benzyl-3-pyrrolidinyl)-5-chloro-4- [(cyclopropylcarbonyl) amino]-2-methoxybenzamide (YM-43611) and related compounds.
    Ohmori J; Maeno K; Hidaka K; Nakato K; Matsumoto M; Tada S; Hattori H; Sakamoto S; Tsukamoto S; Usuda S; Mase T
    J Med Chem; 1996 Jul; 39(14):2764-72. PubMed ID: 8709107
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Acutely administered antipsychotic drugs are highly selective for dopamine D2 over D3 receptors.
    McCormick PN; Wilson VS; Wilson AA; Remington GJ
    Pharmacol Res; 2013 Apr; 70(1):66-71. PubMed ID: 23327779
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Hallucinogenic 5-HT2AR agonists LSD and DOI enhance dopamine D2R protomer recognition and signaling of D2-5-HT2A heteroreceptor complexes.
    Borroto-Escuela DO; Romero-Fernandez W; Narvaez M; Oflijan J; Agnati LF; Fuxe K
    Biochem Biophys Res Commun; 2014 Jan; 443(1):278-84. PubMed ID: 24309097
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Role of the inhibitory adrenergic alpha 2 and serotonergic 5-HT1A components of cocaine's actions on the DOI-induced head-twitch response in 5-HT2-receptor supersensitive mice.
    Darmani NA
    Pharmacol Biochem Behav; 1993 Jun; 45(2):269-74. PubMed ID: 8392199
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Combined serotonin (5-HT)1A agonism, 5-HT(2A) and dopamine D₂ receptor antagonism reproduces atypical antipsychotic drug effects on phencyclidine-impaired novel object recognition in rats.
    Oyamada Y; Horiguchi M; Rajagopal L; Miyauchi M; Meltzer HY
    Behav Brain Res; 2015 May; 285():165-75. PubMed ID: 25448429
    [TBL] [Abstract][Full Text] [Related]  

  • 27. S33138 [N-[4-[2-[(3aS,9bR)-8-cyano-1,3a,4,9b-tetrahydro[1]-benzopyrano[3,4-c]pyrrol-2(3H)-yl)-ethyl]phenylacetamide], a preferential dopamine D3 versus D2 receptor antagonist and potential antipsychotic agent. II. A neurochemical, electrophysiological and behavioral characterization in vivo.
    Millan MJ; Svenningsson P; Ashby CR; Hill M; Egeland M; Dekeyne A; Brocco M; Di Cara B; Lejeune F; Thomasson N; Munoz C; Mocaër E; Crossman A; Cistarelli L; Girardon S; Iob L; Veiga S; Gobert A
    J Pharmacol Exp Ther; 2008 Feb; 324(2):600-11. PubMed ID: 18024787
    [TBL] [Abstract][Full Text] [Related]  

  • 28. An ontogenic study of receptor mechanisms by which acute administration of low-doses of methamphetamine suppresses DOI-induced 5-HT
    Sun Y; Chebolu S; Henry D; Lankireddy S; Darmani NA
    BMC Neurosci; 2022 Jan; 23(1):2. PubMed ID: 34983399
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The antipsychotic trifluoperazine reduces marble-burying behavior in mice via D
    Egashira N; Kubota N; Goto Y; Watanabe T; Kubota K; Katsurabayashi S; Iwasaki K
    Pharmacol Biochem Behav; 2018 Feb; 165():9-13. PubMed ID: 29273456
    [TBL] [Abstract][Full Text] [Related]  

  • 30. New arylpiperazinylalkyl derivatives of 8-alkoxy-purine-2,6-dione and dihydro[1,3]oxazolo[2,3-f]purinedione targeting the serotonin 5-HT1A /5-HT2A /5-HT7 and dopamine D2 receptors.
    Chłoń-Rzepa G; Zagórska A; Bucki A; Kołaczkowski M; Pawłowski M; Satała G; Bojarski AJ; Partyka A; Wesołowska A; Pękala E; Słoczyńska K
    Arch Pharm (Weinheim); 2015 Apr; 348(4):242-53. PubMed ID: 25773907
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Dopamine D1 and D2 agonist effects on prepulse inhibition and locomotion: comparison of Sprague-Dawley rats to Swiss-Webster, 129X1/SvJ, C57BL/6J, and DBA/2J mice.
    Ralph RJ; Caine SB
    J Pharmacol Exp Ther; 2005 Feb; 312(2):733-41. PubMed ID: 15494551
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cariprazine (RGH-188), a dopamine D(3) receptor-preferring, D(3)/D(2) dopamine receptor antagonist-partial agonist antipsychotic candidate: in vitro and neurochemical profile.
    Kiss B; Horváth A; Némethy Z; Schmidt E; Laszlovszky I; Bugovics G; Fazekas K; Hornok K; Orosz S; Gyertyán I; Agai-Csongor E; Domány G; Tihanyi K; Adham N; Szombathelyi Z
    J Pharmacol Exp Ther; 2010 Apr; 333(1):328-40. PubMed ID: 20093397
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Serotonin2 (5-HT2) receptor agonist 1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane (DOI) inhibits chlorpromazine- and haloperidol-induced hypothermia in mice.
    Yamada J; Sugimoto Y; Horisaka K
    Biol Pharm Bull; 1995 Nov; 18(11):1580-3. PubMed ID: 8593484
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A comparison of the discriminative stimulus properties of the atypical antipsychotic drug clozapine in DBA/2 and C57BL/6 inbred mice.
    Porter JH; Walentiny DM; Philibin SD; Vunck SA; Crabbe JC
    Behav Pharmacol; 2008 Sep; 19(5-6):530-42. PubMed ID: 18690107
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The head-twitch response in the least shrew (Cryptotis parva) is a 5-HT2- and not a 5-HT1C-mediated phenomenon.
    Darmani NA; Mock OB; Towns LC; Gerdes CF
    Pharmacol Biochem Behav; 1994 Jun; 48(2):383-96. PubMed ID: 8090805
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Yawning and hypothermia in rats: effects of dopamine D3 and D2 agonists and antagonists.
    Collins GT; Newman AH; Grundt P; Rice KC; Husbands SM; Chauvignac C; Chen J; Wang S; Woods JH
    Psychopharmacology (Berl); 2007 Aug; 193(2):159-70. PubMed ID: 17393143
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Temporal differential adaptation of head-twitch and ear-scratch responses following administration of challenge doses of DOI.
    Darmani NA; Gerdes CF
    Pharmacol Biochem Behav; 1995 Apr; 50(4):545-50. PubMed ID: 7617700
    [TBL] [Abstract][Full Text] [Related]  

  • 38. ACP-103, a 5-hydroxytryptamine 2A receptor inverse agonist, improves the antipsychotic efficacy and side-effect profile of haloperidol and risperidone in experimental models.
    Gardell LR; Vanover KE; Pounds L; Johnson RW; Barido R; Anderson GT; Veinbergs I; Dyssegaard A; Brunmark P; Tabatabaei A; Davis RE; Brann MR; Hacksell U; Bonhaus DW
    J Pharmacol Exp Ther; 2007 Aug; 322(2):862-70. PubMed ID: 17519387
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Brexpiprazole I: in vitro and in vivo characterization of a novel serotonin-dopamine activity modulator.
    Maeda K; Sugino H; Akazawa H; Amada N; Shimada J; Futamura T; Yamashita H; Ito N; McQuade RD; Mørk A; Pehrson AL; Hentzer M; Nielsen V; Bundgaard C; Arnt J; Stensbøl TB; Kikuchi T
    J Pharmacol Exp Ther; 2014 Sep; 350(3):589-604. PubMed ID: 24947465
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Roles of fluoxetine and haloperidol in mouse models of DOI-induced head twitch response].
    Yao Y; Ma HW; Lu Y; Dai XM
    Zhongguo Dang Dai Er Ke Za Zhi; 2007 Oct; 9(5):469-72. PubMed ID: 17937861
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.